- Hermes (HMI TH) +2.2%
- Hermes 1Q Sales at Constant Exchange Rates Beats Estimates
- K+S (SDF TH) +1.8%
- Thyssenkrupp (TKA TH) +1.8%
- German Industry Warns Russian Gas Embargo Is Bad for Business
- Adyen (1N8 TH) +1.5%
- Tomra (TMR TH) +1.4%
- Rio Tinto (RIO1 TH) +1.3%
- Iron Ore Rises as Traders Await Policy Boost For Ailing Economy
- Veolia (VVD TH) +1.1%
- Covestro (1COV TH) +1%
- Vonovia (VNA TH) +0.9%
- Enel (ENL TH) +0.8%
- Equinor (DNQ TH) -1.3%
- Smiths (QS2A TH) -1.7%
- Ericsson (ERCB TH) -4.1%
- Ericsson Says Fines Likely on Iraq Scandal, Misses Estimates
- Delivery Hero (DHER TH) +1.2%
- BMW (BMW TH) +1.1%
- Covestro (1COV TH) +1%
- VW (VOW3 TH) +1%
- E.On (EOAN TH) +1%
- Thyssenkrupp (TKA TH) +2.3%
- German Industry Warns Russian Gas Embargo Is Bad for Business
- K+S (SDF TH) +2.3%
- Lufthansa (LHA TH) +1.2%
- Dermapharm (DMP TH) +3.1%
- PVA TePla (TPE TH) +1.5%
- Deutsche PBB (PBB TH) +1.3%
- Jenoptik (JEN TH) +1.2%
- DWS (DWS TH) +1.2%
- Draegerwerk (DRW3 TH) -6.7%
- Draegerwerk Prelim 1Q Ebit Loss About EU35M
Macro :
- Oil Traders to Cut Russian Oil Purchases Beginning May 15: Rtrs
Keep an eye on :
- CTH LN : Sheikh Holdings Lifts CareTech Offer: M&A Snapshot
* Husqvarna Raised to Hold at DNB Markets; PT 95 kronor
>>> Down
* Galp Cut to Neutral at Goldman; PT 15 euros
>>> Initiation
* Mondo TV Rated New Buy at Integrae SIM; PT 3.10 euros
>>> Call
* Bunzl Cut at Berenberg as Inflationary Tailwinds Set to Ease
After Hours Summary: CMBM -13%, RENT -4% move lower on results/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: N/A
Companies trading higher in after hours in reaction to news: ANSS +2.8% (agreed to acquire OnScale), INMB +1% (dosed first patient in Phase 2 trial of XPro1595), AVNW +0.6% (announced intent to acquire Redline Communications)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CMBM -13.9%, RENT -4.4%
Companies trading lower in after hours in reaction to news: PTGX -36.9% (received letter from FDA indicating intent to rescind Breakthrough Therapy Designation for rusfertide), OCX -18.1% (announced public offering of stock and warrants), AMRX -2.1% (received FDA approval for BLA for bevacizumab-maly), GPC -1.1% (announced acquisition of Lausan Group)